Skip to main content
Phase I study of chimeric human/murine anti-ganglioside G(D2) monoclonal antibody (ch14.18) with granulocyte-macrophage colony-stimulating factor in children with neuroblastoma immediately after hematopoietic stem-cell transplantation: a Children's Cancer
MYCN expression in neuroblastoma: A mixed message?
Loss of heterozygosity at 1p36 independently predicts for disease progression but not decreased overall survival probability in neuroblastoma patients: a Children's Cancer Group study.
Biologic factors determine prognosis in infants with stage IV neuroblastoma: A prospective Children's Cancer Group study.
Favorable biology and outcome of stage IV-S neuroblastoma with supportive care or minimal therapy: a Children's Cancer Group study.
Biologic variables in the outcome of stages I and II neuroblastoma treated with surgery as primary therapy: a children's cancer group study.
Molecular biology of neuroblastoma.
Stage 4S neuroblastoma: what makes it special?
Successful treatment of stage III neuroblastoma based on prospective biologic staging: a Children's Cancer Group study.
Double-alkylator non-total-body irradiation regimen with autologous hematopoietic stem-cell transplantation in pediatric solid tumors.